View the slides for the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy

The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Conclusion Our study showed an increase in the incidence of PN in individuals undergoing treatment of multiple myeloma, 80% had symptoms of neuropathy before and/or during and/or after treatment with chemotherapy regimens. Predominance was of elderly retired men. The most common chemotherapy regimen was bortezomib/dexamethasone/cyclophosphamide and there was no association between regimens used and PN after treatment. The implications of these observations rest on the need for a permanent assessment of PN in people with multiple myeloma, in addition to a strict follow-up to this event in the course of treatment and after i...
Source: Acta Paulista de Enfermagem - Category: Nursing Source Type: research
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma, Published online: 22 October 2018; doi:10.1038/s41408-018-0127-yCD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Cancer Science,Volume 0, Issue ja, -Not available-.
Source: Cancer Science - Category: Cancer & Oncology Authors: Source Type: research
The presence of recurrent genetic mutations in the myeloblasts of patients with acute myeloid leukemia (AML) are prognostic and incorporated into risk stratification systems of both the National Comprehensive Cancer Network and European Leukemia Network.1 In patients with FLT3-internal tandem duplications (FLT3-ITD) or tyrosine kinase domain mutations (TKD) small molecule inhibitors of the resultant mutant proteins in combination with cytotoxic chemotherapy can improve overall survival in newly diagnosed AML patients with a FLT3 mutation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
I realize it’s been quite some TIME since I’ve written a post, almost a MONTH!, so today I decided to sit down and write one, and it’s going to be a long one, so get yourselves some tea and get comfy…    CHAPTER ONE. PEEKABOO: in September I spent a lot of time researching possibly helpful but definitely non-toxic treatments for Peekaboo, my 11-year-old kitty whom I’ve written a lot about in recent times. She has a slipped disc, basically, and has been having a VERY hard time walking. The risk, of course, is that she’d stop walking altogether. Couldn’t let that happen! I...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll Source Type: blogs
Conditions:   Cancer (Colon Cancer, Breast Cancer, Lymphoma, Multiple Myeloma);   Elderly;   Antineoplastic Agents;   Cardiotoxicity Interventions:   Other: Intensive cardiovascular monitoring;   Other: No intervention Sponsors:   Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León;   IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL;   Instituto de Salud Carlos III Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval by the FDA of four HDAC inhibitors, vorinostat, romidepsin, belinostat and panobinostat, used for the treatment of cutaneous/peripheral T-cell lymphoma and multiple myeloma. Many more HDAC inhibitors are in different stages of clinical development for the treatment of hematological malignancie...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
The audit of the Myeloma Institute should be able to determine if there’s any money unaccounted for in the cancer program. The accounting is expected to be final after January.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news
Immortalization of plasma cells leads to Multiple Myeloma (MM). Signaling Lymphocyte Activation Molecule F7 (SLAMF7) is highly expressed on the malignant plasma cells that constitute Multiple Myeloma. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 a promising target for chimeric antigen receptor (CAR) T cell therapies for the treatment of MM.  In addition to expression on normal and malignant plasma cells, SLAMF7 is also known to be expressed on a variety of other leukocytes including most natural killer (NK) cells, some CD8+ T cells, a small fraction of CD4+ T cells, ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Abstract Significant advancements have been made in the molecular mechanisms of myelomagenesis, diagnostic methods, prognostication, and the treatment options in multiple myeloma (MM) over the last decade. Despite these, MM remains a heterogeneous disease with differing outcomes. As myeloma treatment landscape continues to expand, personalized treatment that provides maximum benefit to a specific patient becomes more important. In the last few years, serum monoclonal proteins including the serum-free light chain assays, imaging, and cytogenetics have been used to predict the outcomes of MM patients receiving diffe...
Source: Translational Research : the journal of laboratory and clinical medicine - Category: Laboratory Medicine Authors: Tags: Transl Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Hematology | Immunotherapy | Learning | Myeloma | Universities & Medical Training | University of Pennsylvania